Skip to main content
OpenTrials
Completed

NCT Number: NCT00969072

Extension Study of GI198745 to Treat Benign Prostatic Hyperplasia

The primary objective is to assess the safety of GI198745 0.05mg, 0.5mg, 2.5mg once daily for 52 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Benign Prostatic Hyperplasia Genital Diseases Genital Diseases, Male Male Urogenital Diseases Prostatic Diseases Prostatic Hyperplasia Urogenital Diseases

Age range

50 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

About this study

Upon completion of 24 weeks of GI198745 0.05 mg, 0.5 mg, 2.5 mg, or placebo therapy in study ARI20005, subjects are enrolled into an extension phase and are continued on the same therapy once daily for up to further 28 weeks, followed by up to 16 weeks of post-dosing assessments.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Has been receiving the investigational product for at least 20 weeks in the preceding dose finding study and the investigator or subinvestigator has confirmed the tolerability and has judged as appropriate to participate continuously in further 28 weeks treatment.

Exclusion criteria

  • Is withdrawn from the dose finding study.
  • Has less than 75% compliance with the investigational product in the dose finding study at given the informed consent for the long-term extension study.
  • Has a prostate cancer at giving informed consent for participating in the long-term extension study; or is suspected to have a prostate cancer in palpation, ultrasound imaging, biopsy, etc. at giving informed consent for participating in the long-term extension study.
  • Has the post void residual volume > 250 ml at starting the long-term extension study. (as measured by suprapubic ultrasound).
  • Has chronic bacterial prostatitis or chronic urinary tract infections during the dose finding study
  • Has acute urinary retention in the dose finding study.
  • Has a history or current evidence of drug or alcohol abuse during the dose finding study
  • Has been treated with any investigational product including post-marketing clinical trials during the dose finding study.
  • Has myocardial infarction, coronary arterial bypass surgery, unstable angina, arrhythmia, congestive heart failure, cerebrovascular accident during the dose finding study.
  • Has any concurrent disease or complication that, in the opinion of the investigator/sub-investigator, is difficult to evaluate efficacy of GI198745 in this study and that might poses additional risk to the patient.
  • Is actively trying to procreate in the study period.
  • Is unsuitable for this study, in the opinion of the investigator/sub-investigator.

Treatment and study plan

GI198745 0.05mg

Drug

GI198745 (drug) - benign prostatic hyperplasia

GI198745 0.5mg

Drug

GI198745 (drug) - benign prostatic hyperplasia

GI198745 2.5mg

Drug

GI198745 (drug) - benign prostatic hyperplasia

Primary outcomes

  1. adverse events, laboratory test values (hematology, serum chemistry, electrolyte, and urinalysis), prostate specific antigen (PSA), vital signs (blood pressure, pulse rate), and post-void residual volume.

    Time frame: a 28-week extension treatment in the subjects entered into the 24-week dose finding study (ARI20005: multicentre, double-blind, randomised, placebo-controlled, parallel-group)

Secondary outcomes

  1. prostate volume, symptom scores (IPSS), maximum urinary flow (Qmax), serum dihydrotestosterone (DHT), and testosterone

    Time frame: a 28-week extension treatment in the subjects entered into the 24-week dose finding study (ARI20005: multicentre, double-blind, randomised, placebo-controlled, parallel-group)

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

A Long-term Extension Study of GI198745 in Subjects With Benign Prostatic Hyperplasia

Important dates

Study start
2003
Primary completion
2005
Study completion
2005
First posted
Aug 31, 2009
Registry last updated
Sep 13, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.